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Signiﬁcant decrease in outcomes with statins administration in the
ﬁrst 24 h of an acute myocardial infarction [1–4] and reduction of
myocardial injury markers after high-dose statin given few hours
before percutaneous interventions [5,6] were observed. These effects
of statins take place before lipid changes [7,8]. Clopidogrel, a pro-drug
largely prescribed for patients undergoing stent implantation, is
metabolized in the liver via cytochrome P450 (CYP2C19 and CYP3A4)
to form an active metabolite that inhibits the P2Y(12) ADP platelet
receptor [9,10]. Rosuvastatin is partially metabolized by CYP2C9 and
CYP2C19 [11]. Functional and anatomical changes of the endothelium,
an inﬂammatory substrate and coagulation activation participate on
the pathophysiology of acute coronary syndromes [12,13]. New
biomarkers, such as endothelial and platelet microparticles (EMP and
PMP), endothelial progenitor cells (EPC), platelet function tests and
endothelial-dependent ﬂow-mediated dilation (FMD) have been
proposed for the evaluation of vascular homeostasis [14,15]. Thus, we
examined possible pharmacokinetic interactions between clopidogrel
and rosuvastatin, and the consequences on these biomarkers.
The protocol was in accordance with the ethical standards of the
institution on human experimentation and was approved by the local
ethics committee [16]. Patients (n=20) aging 49 to 77 years, with
stable coronary artery disease were included after having signed a
written informed consent. Enrolled subjects were receiving a stable
dose of statin for at least 3 months. We excluded patientswith baseline
LDL-C above 100 mg/dL to prevent possible consequences of statins
withdrawal [17–20], those with uncontrolled metabolic disorders,
genetic dyslipidemias, class III/IV heart failure [21], andwith intolerance
to the study drugs. Prior statin was discontinued for a week in the
screening visit, when they were scheduled to baseline visit under use of
aspirin 100 mg daily. Fig. 1 summarizes the study design. We evaluated
early effects of rosuvastatin and clopidogrel, alone or combined. All
drugs were supplied to the patients. Biochemistry and lipid proﬁle
analyses were performed in samples obtained after a 12-hour fasting
period in a central laboratory of our university by standard techniques.
EPCs, EMPs and PMPswere determined byﬂowcytometry, as previously
reported [15]. Multiple electrode platelet aggregometer (Multiplate 5.0
Analyzer, Diapharma, Diapharma Group Inc., Munich, BV, Germany)
tests were performed as reported before [22–24]. Aggregation was
induced by collagen (COL), thrombin receptor activating peptide 6
(TRAP-6), adenosine-diphosphate (ADP), and arachidonic acid (ASP),
performed in duplicate.
For pharmacokinetic studies blood sampleswere collected at 0, 0.5,1.0,
1.5, 2.0, 2.5, 3.0, 4.0, 6.0, 8.0, 10.0, 12.0, 16.0 and 24.0 h post-dosing of the
compound of reference. Plasma levels of rosuvastatin and clopidogrel
were measured by using validated liquid chromatography with mass
spectrometry as previously described [25,26]. FMD of the brachial artery
was assessed at eachvisit byultrasound (HP5500)using ahigh-frequency
transducer, aspreviously reported [27].Variableswere comparedbetween
time points using ANOVA-repeated measures followed by Tukey-test or
Friedman test, when appropriate. Pharmacokinetic analyses were
performed as previously described [26]. Tests were two-tailed and
signiﬁcance was set at a p-value b0.05.
Major characteristics of the study participants are shown in Table 1.
Fig. 2 shows remarkable changes on LDL-cholesterol levels after statin
withdrawal (+61%) and introduction (−39%). We observed lower
platelet aggregation to ASP and COL (under aspirin), as well as to ADP
tests (under clopidogrel alone or combinedwith rosuvastatin), whereas
responses toTRAP-6were unchanged (Fig. 3). Improvement in FMDwas
observed 24-h after rosuvastatin initiation and it was maintained up to
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last visit (Fig. 4).Weobservedan interactionwith clopidogrel, increasing
the AUClast and Cmax of rosuvastatin; however, rosuvastatin did not
modify clopidogrel pharmacokinetics (Table 2). There was a trend for
higher levels of CD34+/CD133+ subpopulation of EPCs on visit 3. After
rosuvastatin withdrawal, an increase in the amount of PMP and a trend
for increased levels of EMP were observed (Table 3).
Our study reports interaction between clopidogrel and rosuvasta-
tin, increasing rosuvastatin concentrations. As rosuvastatin is active
independently of its metabolization [28], concomitant clopidogrel
therapy does not reduce its beneﬁts, as per the early and sustained
lipid changes, and the impressive improvement in FMD 24-h after
statin initiation. Abrupt statin withdrawal leads to an overshoot
activation of HMG-CoA reductase, Rho and Rac with loss of the
pleiotropic effects [29]. Rosuvastatin seems to act synergistically with
clopidogrel. Riondino et al. [30] demonstrated neutral effects of
rosuvastatin on platelet inhibition by clopidogrel. Our study showed,
dynamically, the effects of rosuvastatin and clopidogrel introduction/
withdrawal not only on platelet function, but also on EPCs mobiliza-
tion and MPs release. In fact, rosuvastatin withdrawal increased the
amount of PMP, suggesting augmented platelet consumption or
apoptosis [31,32]. The observed trend for lower percentages of EPCs
and higher levels of EMPs 1 week after rosuvastatin withdrawal,
seems to imply the importance of the maintenance of combined
therapy for a more comprehensive cardiovascular protection. Inter-
estingly, the interaction between clopidogrel on plasma levels of
rosuvastatin occurred exclusively after the loading dose (300 mg) and
not with the 75 mg dose. On this view, some pleiotropic effects of
statins in the ﬁrst 24-h of myocardial infarction appear to play an
important role in the early cardiovascular outcomes, and can be due to
recovery of ischemic tissue in areas surrounding the necrotic core,
probably due to the improvement of the microcirculation [33,34].
Most of the absorbed clopidogrel (∼85%) is hydrolyzed by hepatic
carboxylesterase to an inactive carboxylic acid metabolite, and the
remaining ∼15% is converted to an active thiol metabolite in a 2-step
process [9,10]. CYP2C19, CYP1A2, and CYP2B6 isoenzymes are
responsible for the ﬁrst step, whereas CYP2C19, CYP2C9, CYP2B6,
and CYP3A4 are responsible for the second step [9]. The extrapolation
of our ﬁndings to statins that are pro-drugs seems premature. In
addition, liver metabolization by other isoenzymesmay produce other
interactions and lack of synergistic effects with clopidogrel [35,36]. It
is possible that changes in the amount of MPs and EPCs are more
pronounced among statin naïve patients. We suggest a beneﬁcial
synergism between clopidogrel and rosuvastatin, determining a
broader cardiovascular protection than that provided by each drug
alone.
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Fig.1. Study design. FMD=ﬂowmediated dilation of the brachial artery; EMP/PMP=endothelial microparticles/platelet microparticles; EPC=endothelial progenitor cells; §lab tests
include platelet aggregation tests and pharmacokinetic studies for rosuvastatin and clopidogrel; ⁎last dose; †starting dose; ‡loading dose. Rosuvastatin was given at daily dose of
40 mg; clopidogrel loading dose was 300 mg, followed by 75 mg daily. The FMD was performed at time 0 and after 24 h on each visit. Platelet aggregating tests in samples were
obtained at each visit before initiation of therapy. All patients were under stable dose of statin in the last 3 months achieving LDL-C b100 mg/dL. The statin therapy was stopped for a
week prior to visit 1.
Table 1
Baseline characteristics of study population.
Characteristic Values
Patients, n (%) 20 (100)
Age, median (interquartile range) 58 (52–64)
Sex, n (%)
Male 14 (74)
Female 6 (26)
Ethnicity, n (%)
Caucasian 17 (85)
Afro descendant 3 (15)
Weight, kg, mean (SEM) 79.2 (3.1)
Body mass index, kg/m2, mean (SEM) 29.3 (1.0)
Systolic blood pressure, mm Hg, mean (SEM) 121 (3)
Diastolic blood pressure, mm Hg, mean (SEM) 75 (2)
Medical history, n (%)
Prior myocardial infarction 15 (75)
Unstable angina 1 (5)
Stable angina 3 (15)
Coronary artery bypass graft 3 (15)
Percutaneous coronary intervention 13 (65)
Hypertension 18 (90)
Diabetes mellitus 6 (30)
Active smokers 4 (20)
Medications, n (%)
Statins 20 (100)
ACEIs/ARBs 15 (75)
β-blockers 15 (75)
Calcium channel blockers 7 (35)
Diuretics 8 (40)
Aspirin 20 (100)
Nitrates 2 (10)
Sulphonylureas/metformin 7 (35)
Insulin 2 (10)
Fasting glucose, mg/dL, mean (SEM) 104 (4)
Creatinine, mg/dL, mean (SEM) 0.98 (0.04)
CK, IU, mean (SEM) 137 (27)
ALT, IU, mean (SEM) 24 (2)
Baseline characteristics of the study population at visit 1. ACEIs=angiotensin-
converting enzyme inhibitors; ALT=alanine aminotransferase; ARBs=angiotensin II
receptor blockers; CK=creatine phosphokinase. Statins were withdrawn one-week
before.
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Fig. 2. Box-plots showing lipid changes by treatment at each visit. visit 1: ASP=aspirin 100 mg; visit 2: R40=rosuvastatin 40 mg; visit 3: R40/CLO75=rosuvastatin 40mg+clopidogrel
75 mg; visit 4: CLO75=clopidogrel 75 mg. Cholesterol serum levels at visit 1Nvisit 2 and visit 3 (pb0.0001); LDL-cholesterol serum levels at visit 1Nvisit 2 and visit 3 (pb0.0001); HDL-
cholesterol and triglycerides serum values were not changed by treatments (p=0.44 and p=0.17, respectively). All analyses were made by ANOVA–Tukey.
Fig. 3. Box-plots showingplatelet aggregation tests by treatment. Visit 1:ASP=aspirin 100 mg; visit 2:R40=rosuvastatin40 mg;visit 3:R40/CLO75=rosuvastatin 40 mgplus clopidogrel
75 mg; visit 4: CLO75=clopidogrel 75 mg. All samples were obtained with the patients hospitalized immediately before drug administration. ASPtest—activation by arachidonic acid;
COLtest—activationbycollagen;ADPtest—activationbyadenosinediphosphate; TRAPtest—activationby thrombin;AUC=areaunder the curve in aggregationunits. ASPtest: visit 1bvisit 2,
visit 3, andvisit 4 (pb0.0001); COLtest: visit 1bvisit 2, and visit 4 (p=0.008); ADPtest: visit 1 andvisit 2Nvisit 3 and visit 4 (pb0.0001); TRAPtest: unchangedbetween visits (p=0.53). All
analyses were made by ANOVA–Tukey.
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Elevated serum cardiac troponin (cTn) levels are not restricted
to acute coronary syndrome (ACS), but are also frequently
observed in healthy individuals during and after prolonged
endurance-type exercise [1]. The magnitude of exercise-induced
cTn release can vary tremendously among individuals, from
virtually no response to more than ten times the diagnostic
threshold for acute myocardial infarction (AMI) [2]. Studies to
date have examined cTn levels in heterogeneous athlete popula-
tions during single or unstandardized ultra-endurance events,
complicating the identiﬁcation of factors involved, or the mechan-
isms underlying exercise-induced cTn elevations.
Using a homogeneous group of endurance-trained athletes, we
examined exercise-induced cardiac troponin T (cTnT) elevations in a
standardized laboratory-based setting to assess the reproducibility,
identify predisposing factors and obtain evidence for a physiologic or
pathologic nature of this phenomenon. This study was approved by
the Medical Ethical Committee of the Maastricht University Medical
Center and all participants gave written informed consent. Thirty-one
male endurance-trained competitive cyclists (age 25±5 years, body-
weight 73±7 kg, maximal oxygen consumption (VO2max) 60±
5 mL kg− 1 min− 1, weekly training 11±4 h) completed two
identical standardized exercise trials, at a one week interval. The
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